目的探讨抗氧化剂普罗布考、血管紧张素Ⅱ1型受体(AT1R)拮抗剂厄贝沙坦对自发性高血压大鼠(SHR)血压及纤溶酶原激活物抑制物1(PAI-1)的影响。方法 40只SHR随机分为4组,对照组(n=10)、普罗布考组[61mg/(kg·d),n=10]、厄贝沙坦组[50mg/(kg·d),n=10]、联合用药组(普罗布考+厄贝沙坦,n=10);另设同种系雄性WKY大鼠为对照(n=5)。采用灌胃法给药12周,期间尾压法测定大鼠血压。给药结束后,双抗体夹心酶联免疫吸附试验(ELISA)分析法测定血清PAI-1的变化。结果①给药前各组SHR血压差异无统计学意义(P>0.05)。给药12周后,与对照组比较,普罗布考组血压未见明显差异(P>0.05),厄贝沙坦组和联合用药组血压明显降低(P<0.01),联合用药组血压低于厄贝沙坦组(P<0.05)。②4组SHR血清PAI-1含量均高于WKY组。与对照组比较,普罗布考组大鼠血清PAI-1含量无明显差异(P>0.05),而厄贝沙坦、联合用药组大鼠血清PAI-1含量则降低(P<0.01)。结论虽然单独应用普罗布考不能降低SHR血压,但是可以与厄贝沙坦发生协同降压作用,厄贝沙坦可降低SHR血压及血清PAI-1水平。 Objective To investigate the effect of irbesartan, a probucol inhibitor, and angiotensin Ⅱ type 1 receptor (AT1R) antagonist on blood pressure and plasminogen activator inhibitor 1 (PAI-1) in spontaneously hypertensive rats (SHR) Impact. Methods Forty SHRs were randomly divided into 4 groups: control group (n = 10), probucol group (61 mg / (kg · d), n = 10), irbesartan group (50 mg / (kg · d) n = 10], combination therapy group (probucol + irbesartan, n = 10), and other male WKY rats of the same species as control (n = 5). Gavage administration for 12 weeks, during the tail pressure method for determination of rat blood pressure. After administration, the change of PAI-1 in serum was detected by double antibody sandwich enzyme-linked immunosorbent assay (ELISA). Results ① There was no significant difference in SHR blood pressure before administration (P> 0.05). Compared with the control group, there was no significant difference in blood pressure between the probucol group and the control group (P> 0.05). The blood pressure of the irbesartan group and the combination group was significantly lower (P <0.01) Irbesartan group (P <0.05). ② The content of PAI-1 in SHR of 4 groups were higher than that of WKY group. Compared with the control group, serum PAI-1 levels in probucol group had no significant difference (P> 0.05), while serum levels of PAI-1 in irbesartan and combination groups decreased (P <0.01). Conclusions Although probucol alone can not reduce the blood pressure of SHR, it may cooperate with irbesartan in lowering blood pressure and serum PAI-1 level.